Nonmyeloablative Conditioning and Transplantation for Patients With Refractory Systemic Lupus Erythematosus (SLE)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02080195|
Recruitment Status : Terminated (Study was unable to accrue subjects)
First Posted : March 6, 2014
Results First Posted : October 2, 2018
Last Update Posted : October 2, 2018
|Condition or disease||Intervention/treatment||Phase|
|Lupus Erythematosus Graft-versus-host Disease||Drug: Cyclophosphamide Drug: Fludarabine Drug: Tacrolimus Drug: Mycophenolate Mofetil Drug: Rabbit antithymocyte globulin Radiation: Total body irradiation Biological: Allogeneic bone marrow transplant||Phase 1 Phase 2|
Systemic lupus erythematosus (SLE) is a devastating systemic autoimmune disease that predominantly affects young women, is more common in African-Americans than in whites, and results in poor quality of life. Lupus has no cure, and up to 90% of patients require corticosteroids for disease control. More than half of patients with lupus have permanent organ damage, much of which is either directly due to or increased by corticosteroids. To satisfactorily manage moderate-to-severe SLE, the investigators need effective treatments that will allow corticosteroid-sparing.
High-dose chemotherapy followed by autologous BMT or peripheral blood progenitor transplantation (PBSCT) has been proposed as a novel approach to treat severe autoimmune diseases. Allogeneic BMT is not currently utilized for the routine treatment of SLE because of the significant morbidity (GVHD) and mortality associated with the procedure.
The investigators have recently developed an approach to BMT using post-transplant cyclophosphamide that allows us to safely perform allogeneic BMT from matched, mismatched, unrelated or haploidentical donors. Transplant-related mortality, graft-failure and risk of GVHD have been very low with this approach. Furthermore, this approach allows us to greatly expand the donor pool since any patient shares exactly one HLA haplotype with each biological parent or child and half of siblings, an eligible haploidentical donor can be identified rapidly in nearly all cases.
This trial will employ a fludarabine + cyclophosphamide conditioning along with posttransplantation cyclophosphamide on for patients with refractory SLE. The purpose of this trial is to improve the salvage rate for patients with refractory SLE through a reformatting of the immune system.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||1 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Phase I/II Study of Nonmyeloablative Conditioning and Transplantation of Human Leukocyte Antigen (HLA)-Matched, Partially HLA-mismatched, HLA-haploidentical or Matched Unrelated Bone Marrow for Patients With Refractory SLE|
|Actual Study Start Date :||September 13, 2016|
|Actual Primary Completion Date :||March 28, 2017|
|Actual Study Completion Date :||March 29, 2017|
Experimental: Nonmyeloablative Conditioning and BMT
Nonmyeloablative conditioning with rabbit antithymocyte globulin, cyclophosphamide, fludarabine, and total body irradiation. Allogeneic bone marrow transplant on Day 0. Graft versus host disease (GVHD) prophylaxis with cyclophosphamide, mycophenolate mofetil, and tacrolimus.
14.5 mg/kg/day on Days -6 and -5. 50 mg/kg/day on Days 3 and 4.
30 mg/m^2/day on Days -6 through -2.
Other Name: Fludara
Starting on Day 5. Dose will be adjusted according to blood levels.
Drug: Mycophenolate Mofetil
15 mg/kg three times per day from Day 5 to Day 35.
Drug: Rabbit antithymocyte globulin
0.5 mg/kg on Day -9. 2 mg/kg/day on Days -8 and -7.
Other Name: Thymoglobulin
Radiation: Total body irradiation
200 centigray on Day -1.
Biological: Allogeneic bone marrow transplant
Infusion on Day 0.
Other Name: BMT
- The Feasibility of the Conditioning Regimen and Post Transplantation Cyclophosphamide in Refractory SLE Patients With Donors Having Various Degrees of Matching [ Time Frame: 1 year ]Number of participants who were alive at 1 year after transplant and who had not suffered graft rejection, acute or chronic GVHD, or Grade 3 or higher (CTCAE V4.0) adverse events.
- RIFLE Score [ Time Frame: 1 year ]Change in Responder Index for Systemic Lupus Erythematosis (RIFLE) assessment. This is a qualitative scale measuring organ function. The count below is the number of individuals that improved within 1 year.
- Survival [ Time Frame: 1 year ]Number of patients alive and alive without relapse, respectively.
- Graft Failure [ Time Frame: 60 days ]Number of participants with primary and/or secondary graft failure.
- Acute Graft Versus Host Disease (GVHD) [ Time Frame: Up to 2 years ]Percentage of participants who developed grades II-IV and grades III-IV acute GVHD. Acute GVHD is defined by the Przepiorka criteria, which stages the degree of organ involvement in the skin, liver, and gastrointestinal (GI) tract, based on severity, with Stage 1+ being least severe and stage 4+ being the most severe. Grading of acute GVHD is as follows: Grade I (skin involvement stages 1+ to 2+, with no liver or GI involvement), Grade II (skin involvement stages 1+ to 3+, liver 1+, GI tract 1+), Grade III (skin involvement stages 2+ to 3+, liver 1+, GI tract 2+ to 4+), Grade IV (skin involvement stages 4+, Liver 4+).
- Chronic Graft Versus Host Disease (GVHD) [ Time Frame: Up to 2 years ]Percentage of participants who developed chronic GVHD as defined by the NIH consensus criteria. This system gives scores from 0 to 3 for Karnofsky performance score, skin, mouth, eyes, gastrointestinal, liver, lungs, joints, and genitals, as well as an overall severity (mild, moderate, or severe). Higher scores indicate more severe disease. Scores are not totalled or added up.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02080195
|United States, Maryland|
|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|
|Baltimore, Maryland, United States, 21205|
|Principal Investigator:||Javier Bolaños-Meade, MD||The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|